BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (APPROVED BY HEALTH CANADA FOR IBD INDICATIONS)
Remicade®/Johnson & Johnson Innovative Medicine/BioAdvance® (CD 2003, UC 2006)
Remdantry®/Celltrion/Celltrion Connect (2014 previously Inflectra, 2025 renamed Remdantry)
Renflexis®/Organon/Harmony by Organon™ (2018)
Avsola®/Amgen/Amgen Entrust (2025)
Remsima®/Celltrion/Celltrion Connect™ (2024)
Ixifi®/Pfizer/PfizerFlex (2024)
APPROVED CLINICAL INDICATIONS
(may vary within provinces – refer to local patient support program)
Crohn’s disease
Ulcerative colitis
CLASS
Monoclonal antibody
Tumour necrosis factor (TNF) blocking agent
ACTION
IBD causes the immune system to produce an excess amount of TNFα, which causes inflammation. Anti-TNFα is a protein that works to bind TNFα and block inflammation.